Puri Dev R, Wexler Leonard H, Meyers Paul A, La Quaglia Michael P, Healey John H, Wolden Suzanne L
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1177-84. doi: 10.1016/j.ijrobp.2006.02.014. Epub 2006 May 6.
To evaluate local control and toxicity for very young children treated with multimodality therapy for rhabdomyosarcoma (RMS).
From 1990 to 2004, 20 patients<or=36 months at diagnosis were treated at our institution. Nineteen underwent chemotherapy (CMT), surgery and/or intraoperative high-dose-rate brachytherapy (IOHDR), and external-beam radiation (EBRT). Median age was 17 months. Sites included extremity (7), trunk (5), parameningeal (4), orbit (1), head/neck (1), bladder/prostate (1). Histologies consisted of 10 embryonal (53%) and 9 alveolar/undifferentiated (47%). Ten had delayed gross total resection (GTR) at median time of 17 weeks after the start of CMT, and 8 of these underwent IOHDR. Median interval between start of CMT and EBRT was 18 weeks. Median EBRT dose was 36 Gy. EBRT technique was either intensity-modulated (11), three-dimensional (3), or two-dimensional (5). Functional outcome was assessed for patients alive>or=1 year after diagnosis (15) in terms of mild, moderate, or severe deficits.
Median follow-up was 33 months for survivors and 23 months for all patients. Two-year actuarial local control, event-free survival, disease-specific survival, and overall survival were 84%, 52%, 74%, and 62%, respectively. All patients who began EBRT<or=18 weeks after the start of CMT had their disease controlled locally. Five have mild deficits and 10 have no deficits.
A reduced dose of 36-Gy EBRT after delayed GTR may maximize local control while minimizing long-term sequelae for very young children with RMS, but unresectable tumors (e.g., parameningeal) require higher doses. Normal-tissue-sparing techniques such as intensity-modulated radiation therapy and IOHDR are encouraged. Local control may be maximized when EBRT begins <or=18 weeks after initiation of CMT, but further study is warranted. Longer follow-up is required to determine the full extent of late effects.
评估接受多模式治疗的极低龄儿童横纹肌肉瘤(RMS)的局部控制情况和毒性反应。
1990年至2004年,本机构共治疗了20例诊断时年龄≤36个月的患者。19例接受了化疗(CMT)、手术和/或术中高剂量率近距离放疗(IOHDR)以及外照射放疗(EBRT)。中位年龄为17个月。病变部位包括四肢(7例)、躯干(5例)、脑膜旁(4例)、眼眶(1例)、头颈部(1例)、膀胱/前列腺(1例)。组织学类型包括10例胚胎型(53%)和9例肺泡型/未分化型(47%)。10例在CMT开始后中位17周时进行了延迟根治性全切除(GTR),其中8例接受了IOHDR。CMT开始至EBRT的中位间隔时间为18周。EBRT的中位剂量为36 Gy。EBRT技术包括调强放疗(11例)、三维适形放疗(3例)或二维放疗(5例)。对诊断后存活≥1年的患者(15例)的功能结局按照轻度、中度或重度功能缺陷进行评估。
幸存者的中位随访时间为33个月,所有患者的中位随访时间为23个月。2年精算局部控制率、无事件生存率、疾病特异性生存率和总生存率分别为84%、52%、74%和62%。所有在CMT开始后≤18周开始EBRT的患者其疾病均获得局部控制。5例有轻度功能缺陷,10例无功能缺陷。
对于极低龄RMS患儿,延迟GTR后给予36 Gy的较低EBRT剂量可能在使局部控制最大化的同时将长期后遗症最小化,但不可切除的肿瘤(如脑膜旁肿瘤)需要更高剂量。鼓励采用如调强放疗和IOHDR等正常组织保护技术。当EBRT在CMT开始后≤18周开始时局部控制可能最大化,但仍需进一步研究。需要更长时间的随访以确定远期效应的全部范围。